Search Result

Results for "

p38α kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (5) Autophagy (9) Bcr-Abl (1) c-Kit (1) Casein Kinase (11) Drug Isomer (1) Interleukin Related (1) JNK (2) MAPKAPK2 (MK2) (1) MMP (1) Organoid (4) p38 MAPK (43) PGE synthase (1) Pyk2 (1) Raf (2) Reference Standards (7) Src (5) Syk (2) TGF-β Receptor (4) TNF Receptor (1) Wnt (2)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Inflammation/Immunology (34) Metabolic Disease (5) Neurological Disease (5)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10295

SB 202190 Maximum Cited Publications 134 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 is a selective **p38 MAP kinase inhibitor with IC₅₀*s of 50 nM and 100 nM for p38α* and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .

HY-10320

Doramapimod 50+ Cited Publications BIRB 796	p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits B-Raf with an IC₅₀ of 83 nM .

HY-12299

WH-4-023 5 Publications Verification Dual LCK/SRC inhibitor	Src	Cancer
WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC₅₀ of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

HY-10456

TAK-715 10+ Cited Publications	p38 MAPK Casein Kinase Wnt	Inflammation/Immunology
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC₅₀s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits *casein kinase* I (CK1δ/ε)** to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .

HY-139553

Zunsemetinib ATI-450; CDD-450	MAPKAPK2 (MK2)	Inflammation/Immunology
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-107597

Halicin 2 Publications Verification SU3327	JNK	Metabolic Disease Inflammation/Immunology
Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. Halicin shows less active against p38α and Akt kinase .

HY-10295A

SB 202190 hydrochloride Maximum Cited Publications 134 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 hydrochloride is a selective **p38 MAP kinase inhibitor with IC₅₀*s of 50 nM and 100 nM for p38α* and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .

HY-111820

CK1-IN-1	Casein Kinase p38 MAPK	Cardiovascular Disease
CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC₅₀ values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC₅₀ of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis .

HY-108642

AMG-548	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548, an orally active and selective *p38α* inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 inhibits Wnt signaling by directly inhibiting *Casein kinase* 1** isoforms δ and ε .

HY-11087

SD 0006 SD-06	p38 MAPK Autophagy	Inflammation/Immunology
SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of **p38α MAP kinase, with an IC₅₀** of 110 nM for p38α .

HY-16715

Acumapimod 1 Publications Verification BCT197	p38 MAPK Autophagy	Inflammation/Immunology
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC₅₀ of less than 1 μM for p38α.

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective *transforming growth factor-β type I receptor kinase* (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀*=36 nM) and p38α* mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-108642B

AMG-548 dihydrochloride	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548 dihydrochloride, an orally active and selective *p38α* inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 dihydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 dihydrochloride inhibits Wnt signaling by directly inhibiting *Casein kinase* 1** isoforms δ and ε .

HY-112401

p38 MAP Kinase Inhibitor IV	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC₅₀s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .

HY-W015445

SD-169	p38 MAPK	Metabolic Disease
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC₅₀ of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC₅₀ of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .

HY-131335

p38α inhibitor 2	p38 MAPK	Inflammation/Immunology
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC₅₀ of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC₅₀=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .

HY-114221

Org 48762-0 UR13870	p38 MAPK	Inflammation/Immunology
Org 48762-0 (UR13870) is a potent, orally active and selective *p38* inhibitor with an EC₅₀ of 0.1 μM for p38α kinase. Org 48762-0 shows a high degree of kinase selectivity for p38α and p38β over other kinases. Org 48762-0 reduces Lipopolysaccharides (HY-D1056) (LPS)-induced TNFα release. Org 48762-0 can be used for the study of rheumatoid arthritis (RA) and Werner syndrome .

HY-108645

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC₅₀ of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

HY-139553A

(R)-Zunsemetinib (R)-ATI-450; (R)-CDD-450	Drug Isomer	Inflammation/Immunology
(R)-Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-14305

BMS-582949	p38 MAPK	Inflammation/Immunology
BMS-582949 (compound 7k) is an orally active and highly selective p38α MAP kinase inhibitor, with IC₅₀ values of 13 nM for *p38α*, and 50 nM for cellular TNFα. BMS-582949 can be used for research on rheumatoid arthritis .

HY-160930

TOP1288	p38 MAPK Src Syk	Inflammation/Immunology
TOP1288 is a narrow spectrum kinase inhibitor for *P38α, Src* and Syk kinase, with IC₅₀ of 116nM, 24nM and 659nM, respectively. TOP1288 inhibits inflammatory cytokine release from inflamed biopsies and myofibroblasts .

HY-119298

AW-814141	p38 MAPK	Inflammation/Immunology
AW-814141 is a selective and orally active p38 MAP kinase inhibitor. AW-814141 has an IC₅₀ values of 100 nM and 158 nM for *p38-α* and β isoforms, respectively. AW-814141 can inhibit the production of TNF-α induced by LPS (HY-D1056). AW-814141 can inhibit paw edema in rats in a dose-dependent manner. AW-814141 exhibits anti-inflammatory activity and can be used in the research of inflammatory diseases such as rheumatoid arthritis .

HY-14974

R 1487	p38 MAPK	Inflammation/Immunology
R 1487 is an orally active and highly selective p38α mitogen-activated protein kinase inhibitor. R 1487 can be used in the study of rheumatoid arthritis .

HY-10320G

Doramapimod (GMP) BIRB 796 (GMP)	p38 MAPK	Cancer
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC₅₀s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity .

HY-161293

p38-α MAPK-IN-6	p38 MAPK	Cancer
p38-α MAPK-IN-6 (compound 3a) is a *p38α* mitogen-activated protein kinase inhibitor .

HY-105997

AZD 6703	p38 MAPK	Others
AZD 6703 is a p38α MAP kinase inhibitor with activity in inflammatory diseases.

HY-171279

Casein kinase 1δ-IN-29	p38 MAPK Casein Kinase Apoptosis	Inflammation/Immunology
Casein kinase 1δ-IN-29 (Compound 18) is the inhibitor for *p38α* and *casein kinase* 1 that inhibits p38α, CK1δ and CK1ε with IC₅₀** of 0.041 µM, 0.005 µM and 0.447 µM, respectively. Casein kinase 1δ-IN-29 arrests cell cycle at subG1 phase, induces apoptosis in cell AC1-M88 .

HY-171295

p38 Kinase inhibitor 7	p38 MAPK	Inflammation/Immunology
p38 Kinase inhibitor 7 (Comp:XXXIX) is the inhibitor for *p38α* with an IC₅₀ of 5.25 nM. p38 Kinase inhibitor 7 inhibits TNFα production in cell THP-1 with an IC₅₀ of 5.88 nM .

HY-171290

Casein kinase 1δ-IN-31	Casein Kinase p38 MAPK	Inflammation/Immunology
Casein kinase 1δ-IN-31 (Compound 16) is the inhibitor for casein kinase (CK) that inhibits CK1α, CK1δ, and *p38α* with IC₅₀s of 196, 17, and 18 nM, respectively. Casein kinase 1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with IC₅₀ of 1200 nM .

HY-163429

J-1149	TGF-β Receptor p38 MAPK	Inflammation/Immunology Cancer
J-1149 is a potent ALK5 inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research .

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase ALK5 inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-171277

Casein kinase 1δ-IN-27	Casein Kinase p38 MAPK	Cancer
Casein kinase 1δ-IN-27 (Compound 8) is the inhibitor for *casein kinase* 1 that inhibits CK1α, CK1δ, CK1ε, and p38α with IC₅₀*s of 22, 16.5, 9.41 and 14.8 nM, respectively. Casein kinase* 1δ-IN-27 inhibits the DUX4 expression with an IC₅₀ of 10 nM .

HY-10441

BMS-626531	p38 MAPK	Cancer
BMS-626531 is a potent and selective p38α MAP kinase inhibitor. BMS-626531 can be used for the research of cancer .

HY-175432

p38 MAPK-IN-9	p38 MAPK	Inflammation/Immunology
p38 MAPK-IN-9 (Compound 15) is an orally active and highly selective p38α mitogen-activated protein kinase (p38 MAPK) inhibitor with an IC₅₀ value of 9.6 nM. p38 MAPK-IN-9 is promising for research of inflammatory diseases such as rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD) .

HY-10295AR

SB 202190 hydrochloride (Standard)	Organoid Reference Standards p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 (hydrochloride) (Standard) is the analytical standard of SB 202190 (hydrochloride). This product is intended for research and analytical applications. SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .

HY-10320R

Doramapimod (Standard) BIRB 796 (Standard)	Reference Standards p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (Standard) is the analytical standard of Doramapimod. This product is intended for research and analytical applications. Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .

HY-10295R

SB 202190 (Standard)	Organoid Reference Standards p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 (Standard) is the analytical standard of SB 202190. This product is intended for research and analytical applications. SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .

HY-171292

CK1δ-IN-9	Casein Kinase p38 MAPK	Others
CK1δ-IN-9 (Compound 8) is the inhibitor for *casein kinase* 1 that inhibits CK1δ with IC₅₀ of 1.4 nM. CK1δ-IN-9 inhibits p38α and p38β with IC₅₀** of 0.25 μM and 0.78 μM. CK1δ-IN-9 exhibits pharmacokinetic characteristics with a good oral bioavailability (70%) and a moderate clearance .

HY-125387

TOP1210	Src	Inflammation/Immunology
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .

HY-108642A

AMG-548 hydrochloride	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548 hydrochloride, an orally active and selective *p38α* inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 hydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 hydrochloride inhibits Wnt signaling by directly inhibiting *Casein kinase* 1** isoforms δ and ε .

HY-183531

p38 MAP Kinase-IN-4	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase-IN-4 is a p38α MAPK inhibitor with an IC₅₀ of 40.5 nM. p38 MAP Kinase-IN-4 is applicable to inflammation-related research .

HY-18758R

IN-1130 (Standard)	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 (Standard) is the analytical standard of IN-1130. This product is intended for research and analytical applications. IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-125500

TOP1362	p38 MAPK Syk Src	Neurological Disease
TOP1362 is a narrow spectrum *kinase* inhibitor. TOP1362 is a potent inhibitor of *P38-α* and Syk kinases with K_d values of 26 and 18 nM, respectively and an IC₅₀ of 14 nM in the Src kinase activity assay. TOP1362 potently inhibits P38-α, Src and Syk. TOP1362 can be used in the research of dry eye syndrome .

HY-107597R

Halicin (Standard) SU3327 (Standard)	Reference Standards JNK	Metabolic Disease Inflammation/Immunology
Halicin (Standard) is the analytical standard of Halicin (HY-107597). This product is intended for research and analytical applications. Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. Halicin shows less active against p38α and Akt K_inase .

HY-18794

R-03201195	p38 MAPK TNF Receptor Interleukin Related	Inflammation/Immunology
R-03201195 is an efficient and selective p38 MAP kinase inhibitor with an IC₅₀ for *p38α* of 0.7 nM. R-03201195 has inhibitory activity against TNF-α in THP-1 cells and against IL-1β in human whole blood, with IC₅₀ values of 0.25 and 0.57 nM respectively. R-03201195 can be used for inflammatory diseases such as rheumatoid arthritis .

HY-10456R

TAK-715 (Standard)	Reference Standards p38 MAPK Casein Kinase Wnt	Inflammation/Immunology
TAK-715 (Standard) is the analytical standard of TAK-715 (HY-10456). This product is intended for research and analytical applications. TAK-715 is an orally active and potent p38 MAPK inhibitor with IC₅₀s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .

HY-108642BR

AMG-548 dihydrochloride (Standard)	Reference Standards p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548 dihydrochloride (Standard) is the analytical standard of AMG-548 (dihydrochloride) (HY-108642B). This product is intended for research and analytical applications. AMG-548 dihydrochloride, an orally active and selective p38α inhibitor (K_i=0.5 nM), shows slightly selective over p38β (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 dihydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 dihydrochloride inhibits Wnt signaling by directly inhibiting Casein K_inase 1 isoforms δ and ε .

HY-121293

CP-944629	p38 MAPK	Inflammation/Immunology
CP-944629 (Compound 20) is an inhibitor of **p38 alpha kinase with an IC₅₀** of 3.2. CP-944629 can be studied in research for chronic inflammation diseases .

HY-181139

ALK5-IN-86	Anaplastic lymphoma kinase (ALK)	Metabolic Disease
ALK5-IN-86 (Compound 22f) is a selective ALK5 inhibitor with an IC₅₀ of 0.267 μM. ALK5-IN-86 forms hydrogen bonds with key amino acid residues in the active site of ALK5. ALK5-IN-86 is applicable to the research of diseases such as liver fibrosis .

HY-18909

Multi-kinase-IN-11	Src Bcr-Abl Pyk2 p38 MAPK c-Kit	Others
Multi-kinase-IN-11 (Compound 1a) is a DFG-out conformation-targeted multi-kinase inhibitor, including SRC, LCK, ABL, PYK2, CSK, HCK, P38 and C-KIT. Multi-kinase-IN-11 serves as a scaffold for the preparation of fluorescently labeled binding probes and affinity matrices .

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3) Rat (2) Mouse (3)
Application:	IHC-P (1) ICC/IF (3) IP (1) WB (3) FC (1) ELISA (3)
Isotype:	IgG (2) IgG1 (1)
Conjugation:	Non-conjugated (3)
Clonality:	Polyclonal (1) Monoclonal (2)
Modification:	Phosphorylated (1) Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85712

	p38 alpha/MAPK14 Antibody (YA5404) Mitogen-activated protein kinase 14; MAP kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding protein; CSAID-binding protein; CSBP; MAP kinase MXI2; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MAP kinase p38 alpha; Stress-activated protein kinase 2a; SAPK2a;	WB, ICC/IF, ELISA	Human, Mouse, Rat
	p38 alpha/MAPK14 Antibody (YA5404) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p38 alpha/MAPK14.

HY-P86460

	p38 alpha/MAPK14 Antibody (YA6152) Mitogen-activated protein kinase 14; MAP kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding protein; CSAID-binding protein; CSBP; MAP kinase MXI2; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MAP kinase p38 alpha; Stress-activated protein kinase 2a; SAPK2a;	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	p38 alpha/MAPK14 Antibody (YA6152) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 alpha/MAPK14.

HY-P80776A

	Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody 1 Publications Verification p38 (phospho T180 + Y182); p-p38 (phospho T180 + Y182); p38 (phospho T180/Y182); CSAID Binding Protein 1; CSAID binding protein; CSAID-binding protein; Csaids binding protein; CSBP 1; CSBP 2; CSBP; CSBP1; CSBP2; CSPB 1; CSPB1; Cytokine suppressive anti inflammatory drug binding protein; Cytokine suppressive anti-inflammatory drug-binding protein; EXIP; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAPK14; MAX interacting protein 2; MAX-interacting protein 2; Mitogen Activated Protein kinase 14; Mitogen activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; Mitogen-activated protein kinase p38 alpha; MK14_HUMAN; Mxi 2; Mxi2; p38 ALPHA; p38; p38 MAP kinase; p38 MAPK; p38 mitogen activated protein kinase; p38ALPHA; p38alpha Exip; PRKM14; PRKM15; RK; SAPK 2A; SAPK2A; Stress Activated Protein kinase 2A.	WB, IHC-P, FC, ICC/IF, ELISA	Human, Mouse
	Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-p38 alpha/MAPK14 (Thr180+Tyr182).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-125387

TOP1210		Alkynes
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: